Xuzhou Medical University, Xuzhou, JiangSu, China.
Affiliated Hospital of Xuzhou Medical University, Xuzhou, JiangSu, China.
Support Care Cancer. 2023 Aug 7;31(9):510. doi: 10.1007/s00520-023-07976-0.
Evaluating the intervention effect of PC6 acupressure on chemotherapy-induced acute, delayed nausea, and vomiting in malignant tumor patients.
Eleven databases had been retrieved from January 2010 through January 2022. The published meta-analysis literature was hand-searched, and the language was limited to English and Chinese. The protocol of this meta-analysis was registered with PROSPERO (registration number: CRD42022323693). Two reviewers independently selected relevant eligible articles, extracted data, and evaluated the risk of bias. Meta-analysis was statistically analyzed using software RevMan 5.3.
Ten randomized controlled trials with 975 patients were included. Only two studies were assessed as high quality; eight studies were evaluated as moderate. Meta-analysis showed that compared with the control group, PC6 acupressure reduced the occurrence number of acute (SMD = -0.39,95CI (-0.73, -0.05) P = 0.02), delayed (SMD = -0.51, 95% CI (-0.96, -0.05) P = 0.03) nausea and acute (SMD = -0.42,95% CI (-0.79, -0.06) P = 0.02), delayed (SMD = -0.37, 95% CI (-0.77, 0.03) P = 0.07) vomiting; it reduced the severity of acute (SMD = -0.34, 95% CI (-0.57, -0.11) P = 0.004), delayed (SMD = -0.79, 95% CI (-1.33, -0.25) P = 0.004) nausea and acute (SMD = -0.51, 95% CI (-0.79, -0.23) P = 0.0004), delayed (SMD = -0.50, 95% CI (-0.84, -0.17) P = 0.003) vomiting, while it did not reduced the experience time on acute and delayed CINV.
The meta-analysis shows the effectiveness of PC6 acupressure in preventing and treating nausea and vomiting. Large, high-quality, well-designed randomized controlled trials are needed in the future to determine the efficacy of PC6 acupressure on chemotherapy-induced nausea and vomiting.
评估 PC6 穴位按压对恶性肿瘤患者化疗引起的急性、迟发性恶心和呕吐的干预效果。
检索 2010 年 1 月至 2022 年 1 月的 11 个数据库。手工检索发表的荟萃分析文献，语言限于英文和中文。该荟萃分析的方案已在 PROSPERO（注册号：CRD42022323693）上注册。两名审查员独立选择相关合格文献，提取数据并评估偏倚风险。使用 RevMan 5.3 软件进行统计学分析。
纳入了 10 项随机对照试验，共 975 名患者。仅有两项研究被评为高质量，八项研究被评为中等质量。荟萃分析显示，与对照组相比，PC6 穴位按压可减少急性（SMD = -0.39，95%CI（-0.73，-0.05）P=0.02）、迟发性（SMD = -0.51，95%CI（-0.96，-0.05）P=0.03）恶心和急性（SMD = -0.42，95%CI（-0.79，-0.06）P=0.02）、迟发性（SMD = -0.37，95%CI（-0.77，0.03）P=0.07）呕吐的发生次数；可降低急性（SMD = -0.34，95%CI（-0.57，-0.11）P=0.004）、迟发性（SMD = -0.79，95%CI（-1.33，-0.25）P=0.004）恶心和急性（SMD = -0.51，95%CI（-0.79，-0.23）P=0.0004）、迟发性（SMD = -0.50，95%CI（-0.84，-0.17）P=0.003）呕吐的严重程度，但不减少急性和迟发性 CINV 的体验时间。
荟萃分析表明，PC6 穴位按压在预防和治疗恶心和呕吐方面具有有效性。未来需要进行更大规模、高质量、精心设计的随机对照试验，以确定 PC6 穴位按压对化疗引起的恶心和呕吐的疗效。
